Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.686 USD | -0.82% | -2.96% | +34.89% |
Financials (USD)
Sales 2024 * | 98.05M | Sales 2025 * | 83.06M | Capitalization | 82.56M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -48M | EV / Sales 2024 * | 0.36 x |
Net cash position 2024 * | 47.51M | Net cash position 2025 * | 57.37M | EV / Sales 2025 * | 0.3 x |
P/E ratio 2024 * |
-0.87
x | P/E ratio 2025 * |
-2
x | Employees | 225 |
Yield 2024 * |
289% | Yield 2025 * |
289% | Free-Float | 94.1% |
Latest transcript on Atara Biotherapeutics, Inc.
1 day | -3.25% | ||
1 week | -2.96% | ||
Current month | -0.33% | ||
1 month | +16.13% | ||
3 months | -5.25% | ||
6 months | -53.58% | ||
Current year | +34.89% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | - | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 15-03-25 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.6917 | -3.25% | 830 302 |
24-04-17 | 0.7149 | +4.89% | 832,651 |
24-04-16 | 0.6816 | +0.44% | 1,024,577 |
24-04-15 | 0.6786 | -4.15% | 1,722,231 |
24-04-12 | 0.708 | -0.67% | 1,188,873 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.89% | 82.56M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-0.44% | 21.66B | |
-18.35% | 20.77B | |
-7.45% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- ATRA Stock